News for Quest PharmaTech Inc. (QPTFF)

EDMONTON, Alberta, Oct. 11, 2024 (GLOBE NEWSWIRE) — Quest PharmaTech Inc. (TSX-V:QPT) (“Quest” or the “Company”) today announced the results of its October 8, 202…

“Photodynamic Therapy Devices Market” from 2024-2034 with covered segments By Product Type (Photosensitizer Drugs, Aminolevulinic Acid, Porphyrin...

Quest PharmaTech Inc. announced that it has received information that the Phase III clinical trial of oregovomab for the treatment of Ovarian Cancer, sponsored by CanariaBio Inc. , has received...

One of the primary growth drivers for the PDT market is the rising incidence of cancer and skin diseases globally. PDT is particularly effective in...

/PRNewswire/ -- According to a comprehensive research report by Brandessence Market Research (BMRC), "Photodynamic Therapy Market Overview, Component, Industry...

Emerging applications in ophthalmology is a major factor that is anticipated to escalate the photodynamic therapy market growth...

A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER September 30, 2022 Fellow shareholders, We are pleased to invite you to... | October 5, 2022

An increase in the prevalence of various skin diseases, such as psoriasis, actinic keratosis, acne, rosacea, and others is leading to the growth of the...

TSX Venture: QPT  EDMONTON, AB, July 7, 2021 /CNW/ - Quest PharmaTech Inc. (TSX-V: QPT) ('Quest' or the 'Company') today announced the results of ...

/PRNewswire/ - Quest PharmaTech Inc. (TSXV: QPT) ("Quest" or the "Company") announces that clinical investigators working with OncoQuest Pharmaceuticals, Inc....

TSX Venture: QPT                                                                      EDMONTON, AB, June 1, 2021 /PRNewswire/ - Quest PharmaTech Inc. (TSXV: